When a more targeted gene panel test was initially performed in our laboratory, this test allows for comprehensive reanalysis of a larger set of genes/gene regions
Evaluation of hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for clinical management
This test includes next-generation sequencing to evaluate for the following 42 genes and select intronic regions: ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A,ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SRP72, SMC3, SRSF2, STAG2,TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.
Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel sample submission.
This is a bioinformatics and variant review only for the added gene regions.
See Targeted Genes Interrogated by OncoHeme Next-Generation Sequencing in Special Instructions for a list of the genes and exons targeted by this test. Call 800-533-1710 for assistance with ordering.
Only orderable as a reflex. For more information see NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel.
Somatic Mutation Detection by Next-Generation Sequencing (NGS)
